Real-world study of the use of azacitidine in myelodysplasia in Australia.

Autor: Enjeti A; Faculty of Medicine and Public Health University of Newcastle Newcastle New South Wales Australia.; Department of Haematology Calvary Mater Hospital Newcastle New South Wales Australia., Ashraf A; Department of Haematology Calvary Mater Hospital Newcastle New South Wales Australia., Caillet V; Prospection Pty Ltd. Sydney New South Wales Australia., Alam A; Prospection Pty Ltd. Sydney New South Wales Australia., Silar J; Faculty of Medicine and Public Health University of Newcastle Newcastle New South Wales Australia.; Department of Haematology Calvary Mater Hospital Newcastle New South Wales Australia., Keer H; Astex Pharmaceuticals, Inc. Pleasanton California USA., Castaldi F; Otsuka Australia Pharmaceutical Chatswood New South Wales Australia., Paine T; Otsuka Australia Pharmaceutical Chatswood New South Wales Australia.
Jazyk: angličtina
Zdroj: EJHaem [EJHaem] 2024 May 17; Vol. 5 (3), pp. 527-534. Date of Electronic Publication: 2024 May 17 (Print Publication: 2024).
DOI: 10.1002/jha2.911
Abstrakt: Hypomethylating agents are the most widely used upfront therapy for patients with myelodysplastic syndrome (MDS) who are not suitable for hematopoietic stem cell transplantation. In Australia, azacitidine was, until recently, the only approved and subsidized treatment for patients with intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and low blast acute myeloid leukemia. We analyzed prescription data to evaluate the real-world persistence and overall survival (OS) of patients prescribed azacitidine for the first time in Australia. A retrospective cohort analysis of patients who had been prescribed Pharmaceutical Benefits Scheme (PBS)-listed azacitidine for the first time, between January 2016 and April 2021, was conducted using the PBS 10% dataset. Treatment persistence and OS were estimated using Kaplan-Meier methods. The impact of the number of treatment cycles and treatment adherence on OS was also estimated. There were 351 patients in the PBS 10% dataset who initiated treatment with azacitidine. The average age (standard deviation [SD]) at azacitidine initiation was 71.9 (11.1) years and the average number (SD) of azacitidine prescriptions was 5.6 (0.2). The median persistence on azacitidine was 15.6 months, and the OS was 13.4 months. The median OS for patients who had six or more cycles of azacitidine treatment was greater compared to patients who had five or less cycles of treatment. The data from this real-world study illustrate the unmet medical needs of patients with MDS treated with azacitidine in Australia. The majority of patients are not treated with the optimal number of cycles of azacitidine, which is negatively correlated with patient outcomes.
Competing Interests: Anoop Enjeti has acted as an advisor and received honoraria on speaker panel for ASTEX/OTSUKA. The authors declare no conflicts of interest specifically related to this retrospective review. Francesco Castaldi and Taleisha Paine are employees of ASTEX/OTSUKA but are not the commercial manufacturers of any of the drugs analyzed in this PBS dataset analysis. Harold Keer was employed by ASTEX Pharmaceuticals, Inc. (USA) during manuscript development. Harold Keer is currently employed by Taiho Oncology, Inc. (USA). Asma Ashraf, Jonathan Silar, Vincent Caillet, and Arif Alam declare they have no conflicts of interest.
(© 2024 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: